Vaccines have proven to be a boon for animal health in veterinary medicine. With increase in the number of adoption cases of companion animals globally, vaccination has become important for these animals as they suffer from various diseases. Strong focus on the development of needle-free DNA animal vaccines and ongoing research on plant-based animal vaccines have added to the growth of the market.
Other than this, growth in livestock population and repeated outbreaks of life-stock diseases; rising incidence of zootonic diseases; introduction of new vaccines; and government initiatives by various agencies, animal associations, and major market players are also boosting the growth of the global animal vaccines market.
Based on technology, the animal vaccines market has been bifurcated into live attenuated, toxoid, inactivated, DNA, recombinant, and subunit/conjugate vaccines. As live attenuated vaccines have a rare chance of reverting to a pathogenic form, these vaccines held the largest share in the market in the historical period and are expected to continue with the trend in the forecast period. DNA vaccines is the fastest growing category in this market, owing to thermo-stability, cost effectiveness, easy production, and rapid vaccine development against emerging diseases in animals.
Geographically, North America is expected to lead the global animal vaccines market in the coming years, owing to the stringent regulations for vaccines production, increasing awareness against the use of antimicrobials, and rising number of innovations in developing vaccines for animals in the region.
Various factors, including, rising technological innovations and introduction of innovative vaccines; such as DNA, and recombinant vaccines; improved healthcare facilities; and growing investment by government bodies are positively impacting the growth of this market. Recombinant vaccines represent an innovative option to overcome the limitations of conventional vaccines, since these can be produced efficiently in large amounts and usually present low reactogenicity and toxicity.
Emerging economies offer immense opportunities to the market players in terms of rapidly growing healthcare infrastructure and increasing expenditure, due to which the manufacturers in the animal vaccines industry can easily invest in these economies and generate higher revenue.
Moreover, PHARMAQ, a business of Zoetis Inc., signed a partnership agreement with Vin Hoan Corporation, during a VIETFISH exhibition, in August 2018, to involve large scale vaccination of pangasius with ALPHA JECT Panga 2, a PHARMAQ vaccine that protects against disease caused by the bacteria Edwardsiella ictaluri and Aeromonas hydrophila. Under the terms of the agreement, PHARMAQ has also agreed to provide Vinh Hoan Corporation with fish health services, diagnostic testing, and the introduction of new technologies and R&D activities.
Other than Zoetis Inc, the animal vaccines industry is marked by the presence of market players, such as Merck & Co. Inc., C.H. Boehringer Sohn AG & Ko. KG, Eli Lilly and Company, Ceva Santé Animale S.A., Virbac Group, Bayer AG, Vetoquinol S.A., Phibro Animal Health Corporation, and Hester Biosciences Limited.
Read more: https://www.psmarketresearch.com/market-analysis/animal-vaccines-market
Other than this, growth in livestock population and repeated outbreaks of life-stock diseases; rising incidence of zootonic diseases; introduction of new vaccines; and government initiatives by various agencies, animal associations, and major market players are also boosting the growth of the global animal vaccines market.
 |
| To Learn more About this Report@ http://bit.ly/38PEFR8 |
Geographically, North America is expected to lead the global animal vaccines market in the coming years, owing to the stringent regulations for vaccines production, increasing awareness against the use of antimicrobials, and rising number of innovations in developing vaccines for animals in the region.
Various factors, including, rising technological innovations and introduction of innovative vaccines; such as DNA, and recombinant vaccines; improved healthcare facilities; and growing investment by government bodies are positively impacting the growth of this market. Recombinant vaccines represent an innovative option to overcome the limitations of conventional vaccines, since these can be produced efficiently in large amounts and usually present low reactogenicity and toxicity.
Emerging economies offer immense opportunities to the market players in terms of rapidly growing healthcare infrastructure and increasing expenditure, due to which the manufacturers in the animal vaccines industry can easily invest in these economies and generate higher revenue.
Moreover, PHARMAQ, a business of Zoetis Inc., signed a partnership agreement with Vin Hoan Corporation, during a VIETFISH exhibition, in August 2018, to involve large scale vaccination of pangasius with ALPHA JECT Panga 2, a PHARMAQ vaccine that protects against disease caused by the bacteria Edwardsiella ictaluri and Aeromonas hydrophila. Under the terms of the agreement, PHARMAQ has also agreed to provide Vinh Hoan Corporation with fish health services, diagnostic testing, and the introduction of new technologies and R&D activities.
Other than Zoetis Inc, the animal vaccines industry is marked by the presence of market players, such as Merck & Co. Inc., C.H. Boehringer Sohn AG & Ko. KG, Eli Lilly and Company, Ceva Santé Animale S.A., Virbac Group, Bayer AG, Vetoquinol S.A., Phibro Animal Health Corporation, and Hester Biosciences Limited.
Read more: https://www.psmarketresearch.com/market-analysis/animal-vaccines-market
No comments:
Post a Comment